# Wesbanco Inc: financial statements, quarterly

WSBC · Nasdaq · CIK 203596 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wsbc.md) · [Financials](/companies/wsbc/financials.md) · [Filings](/companies/wsbc/filings.md) · [Insiders](/companies/wsbc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wsbc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [73.6 d](/filings/0000950170-24-020323.md) | [81.4](/filings/0000950170-24-052154.md) | [86.4](/filings/0000950170-24-089351.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [8.6 d](/filings/0001193125-26-085463.md) | [7.7](/filings/0000950170-25-067145.md) | [6.1](/filings/0000950170-25-105102.md) | [7.5](/filings/0001193125-25-274353.md) | [12.3 d](/filings/0001193125-26-085463.md) | [(0.7)](/filings/0001193125-26-197299.md) | [13.6](/filings/0001193125-26-326145.md) | [19.7](/filings/0001193125-26-437801.md) | [23.5 d](/filings/0001193125-26-085463.md) | [22.8](/filings/0001193125-26-197299.md) | [24.8](/filings/0001193125-26-326145.md) | [23.7](/filings/0001193125-26-437801.md) |
| Net income | $m | [35.0 d](/filings/0001193125-26-085463.md) | [35.7](/filings/0000950170-25-067145.md) | [28.9](/filings/0000950170-25-105102.md) | [37.3](/filings/0001193125-25-274353.md) | [49.6 d](/filings/0001193125-26-085463.md) | [(9.0)](/filings/0001193125-26-197299.md) | [57.4](/filings/0001193125-26-326145.md) | [83.6](/filings/0001193125-26-437801.md) | [91.1 d](/filings/0001193125-26-085463.md) | [88.6](/filings/0001193125-26-197299.md) | [92.7](/filings/0001193125-26-326145.md) | [89.5](/filings/0001193125-26-437801.md) |
| Diluted EPS | $ per share | not reported | [0.56](/filings/0000950170-25-067145.md) | [0.44](/filings/0000950170-25-105102.md) | [0.54](/filings/0001193125-25-274353.md) | not reported | [(0.15)](/filings/0001193125-26-197299.md) | [0.57](/filings/0001193125-26-326145.md) | [0.84](/filings/0001193125-26-437801.md) | not reported | [0.88](/filings/0001193125-26-197299.md) | [0.91](/filings/0001193125-26-326145.md) | [0.88](/filings/0001193125-26-437801.md) |
| Basic EPS | $ per share | not reported | [0.56](/filings/0000950170-25-067145.md) | [0.44](/filings/0000950170-25-105102.md) | [0.54](/filings/0001193125-25-274353.md) | not reported | [(0.15)](/filings/0001193125-26-197299.md) | [0.57](/filings/0001193125-26-326145.md) | [0.84](/filings/0001193125-26-437801.md) | not reported | [0.88](/filings/0001193125-26-197299.md) | [0.92](/filings/0001193125-26-326145.md) | [0.89](/filings/0001193125-26-437801.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.6](/filings/0000950170-25-030795.md) | [0.5](/filings/0000950170-24-052154.md) | [0.5](/filings/0000950170-24-089351.md) | [0.6](/filings/0000950170-24-119518.md) | [0.6](/filings/0001193125-26-085463.md) | [1.1](/filings/0000950170-25-067145.md) | [1.2](/filings/0000950170-25-105102.md) | [1.0](/filings/0001193125-25-274353.md) | [1.0](/filings/0001193125-26-437801.md) | [1.0](/filings/0001193125-26-197299.md) | [0.9](/filings/0001193125-26-326145.md) | [1.0](/filings/0001193125-26-437801.md) |
| Total assets | $bn | [17.7](/filings/0000950170-25-030795.md) | [17.8](/filings/0000950170-24-052154.md) | [18.1](/filings/0000950170-24-089351.md) | [18.5](/filings/0000950170-24-119518.md) | [18.7](/filings/0001193125-26-085463.md) | [27.4](/filings/0000950170-25-067145.md) | [27.6](/filings/0000950170-25-105102.md) | [27.5](/filings/0001193125-25-274353.md) | [27.7](/filings/0001193125-26-437801.md) | [27.5](/filings/0001193125-26-197299.md) | [27.8](/filings/0001193125-26-326145.md) | [28.5](/filings/0001193125-26-437801.md) |
| Total liabilities | $bn | [15.2](/filings/0000950170-25-030795.md) | [15.2](/filings/0000950170-24-052154.md) | [15.6](/filings/0000950170-24-089351.md) | [15.7](/filings/0000950170-24-119518.md) | [15.9](/filings/0001193125-26-085463.md) | [23.6](/filings/0000950170-25-067145.md) | [23.8](/filings/0000950170-25-105102.md) | [23.4](/filings/0001193125-25-274353.md) | [23.7](/filings/0001193125-26-437801.md) | [23.4](/filings/0001193125-26-197299.md) | [23.7](/filings/0001193125-26-326145.md) | [24.4](/filings/0001193125-26-437801.md) |
| Shareholders' equity | $bn | [2.5](/filings/0001193125-26-085463.md) | [2.5](/filings/0000950170-25-105102.md) | [2.5](/filings/0001193125-25-274353.md) | [2.8](/filings/0001193125-25-274353.md) | [2.8](/filings/0001193125-26-437801.md) | [3.8](/filings/0001193125-26-326145.md) | [3.8](/filings/0001193125-26-437801.md) | [4.1](/filings/0001193125-26-437801.md) | [4.0](/filings/0001193125-26-437801.md) | [4.1](/filings/0001193125-26-326145.md) | [4.1](/filings/0001193125-26-437801.md) | [4.1](/filings/0001193125-26-437801.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [47.4 d](/filings/0001193125-26-085463.md) | [64.6](/filings/0000950170-25-067145.md) | [18.2 d](/filings/0000950170-25-105102.md) | [60.7 d](/filings/0001193125-25-274353.md) | [67.4 d](/filings/0001193125-26-085463.md) | [(26.4)](/filings/0001193125-26-197299.md) | [105 d](/filings/0001193125-26-326145.md) | [117 d](/filings/0001193125-26-437801.md) | [94.9 d](/filings/0001193125-26-085463.md) | [107](/filings/0001193125-26-197299.md) | [77.7 d](/filings/0001193125-26-326145.md) | [113 d](/filings/0001193125-26-437801.md) |
| Capital expenditure | $m | [2.9 d](/filings/0001193125-26-085463.md) | [2.8](/filings/0000950170-25-067145.md) | [(0.9) d](/filings/0000950170-25-105102.md) | [3.8 d](/filings/0001193125-25-274353.md) | [4.6 d](/filings/0001193125-26-085463.md) | [4.3](/filings/0000950170-25-067145.md) | [6.8 d](/filings/0000950170-25-105102.md) | [2.0 d](/filings/0001193125-25-274353.md) | [(2.7) d](/filings/0001193125-26-085463.md) | not reported | not reported | not reported |
| Dividends paid | $m | [20.6 d](/filings/0001193125-26-085463.md) | [21.2](/filings/0000950170-25-067145.md) | [21.2 d](/filings/0000950170-25-105102.md) | [21.2 d](/filings/0001193125-25-274353.md) | [23.8 d](/filings/0001193125-26-085463.md) | [24.5](/filings/0001193125-26-197299.md) | [35.2 d](/filings/0001193125-26-326145.md) | [35.2 d](/filings/0001193125-26-437801.md) | [30.3 d](/filings/0001193125-26-085463.md) | [36.9](/filings/0001193125-26-197299.md) | [36.2 d](/filings/0001193125-26-326145.md) | [36.2 d](/filings/0001193125-26-437801.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [59.4](/filings/0000950170-24-052154.md) | [59.4](/filings/0000950170-24-089351.md) | [59.4](/filings/0000950170-24-119518.md) | [59.5](/filings/0000950170-25-067145.md) | [59.7](/filings/0000950170-25-105102.md) | [64.6](/filings/0001193125-25-274353.md) | [77.0](/filings/0001193125-26-197299.md) | [95.8](/filings/0001193125-26-326145.md) | [96.1](/filings/0001193125-26-437801.md) | [96.3](/filings/0001193125-26-197299.md) | [96.7](/filings/0001193125-26-326145.md) | [96.6](/filings/0001193125-26-437801.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 95,985,127 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-437801.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:32 ET. No prices; not investment advice.